$183 Million is the total value of Prosight Management, LP's 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 69.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALBO | Sell | ALBIREO PHARMA INC | $10,518,149 | +10.6% | 486,726 | -0.9% | 5.74% | +12.6% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $10,242,000 | -45.4% | 90,000 | -70.3% | 5.58% | -44.4% |
| ALKS | Sell | ALKERMES PLC | $8,923,944 | -20.4% | 341,521 | -32.0% | 4.87% | -19.0% |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $5,976,615 | -7.6% | 858,709 | -29.1% | 3.26% | -5.9% |
| Sell | QUIDELORTHO CORP | $4,283,500 | -4.7% | 50,000 | -20.5% | 2.34% | -3.0% | |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $630,017 | -80.3% | 32,193 | -83.9% | 0.34% | -79.9% |
| EOLS | Sell | EVOLUS INC | $498,949 | -61.3% | 66,438 | -58.5% | 0.27% | -60.6% |
| MRVI | Exit | MARAVAI LIFESCIENCES HLDGS I | $0 | – | -8,540 | -100.0% | -0.12% | – |
| SPOK | Exit | SPOK HLDGS INC | $0 | – | -65,000 | -100.0% | -0.27% | – |
| Exit | R1 RCM INC | $0 | – | -32,113 | -100.0% | -0.32% | – | |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -196,257 | -100.0% | -0.56% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -1,716,290 | -100.0% | -0.68% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -1,126,127 | -100.0% | -0.72% | – |
| ONEM | Exit | 1LIFE HEALTHCARE INC | $0 | – | -106,200 | -100.0% | -0.98% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -1.05% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -39,000 | -100.0% | -1.13% | – |
| AVTR | Exit | AVANTOR INC | $0 | – | -122,668 | -100.0% | -1.29% | – |
| OMCL | Exit | OMNICELL COM | $0 | – | -30,700 | -100.0% | -1.43% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -40,450 | -100.0% | -1.44% | – |
| Exit | PROTHENA CORP PLCcall | $0 | – | -53,100 | -100.0% | -1.72% | – | |
| JNJ | Exit | JOHNSON & JOHNSON | $0 | – | -31,704 | -100.0% | -2.78% | – |
| THC | Exit | TENET HEALTHCARE CORP | $0 | – | -102,000 | -100.0% | -2.82% | – |
| CRL | Exit | CHARLES RIV LABS INTL INC | $0 | – | -33,220 | -100.0% | -3.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.